MK-677 for 90 days: separating growth hormone claims from evidence

A recent TikTok clip asks what happens if you take MK-677 for 90 days, implying noticeable gains in muscle and recovery. The caption is short, but the implication is clear: a three-month cycle yields tangible results. But what does the research actually say about MK-677 and similar growth hormone secretagogues? This article separates the hype from the evidence.

What the clip claims

The video suggests that 90 days of MK-677 leads to meaningful changes—likely increased muscle mass, better recovery, or improved sleep. It does not mention side effects, individual variability, or the fact that results are often modest and not universally replicated. The 90-day timeframe is presented as a magic threshold, but no specific outcome is defined.

What the research neighborhood covers

MK-677 (ibutamoren) is an orally active growth hormone secretagogue that mimics ghrelin, stimulating the pituitary to release growth hormone. It is not a peptide itself but is often discussed alongside peptides like Ipamorelin, Hexarelin, and GHRP-6—all of which act on the ghrelin receptor. The research on these compounds focuses on growth hormone pulse amplitude, IGF-1 levels, and downstream effects on body composition and recovery.

Human studies on MK-677 are limited but do exist. Some trials in older adults or growth hormone-deficient patients show increases in lean body mass and fat-free mass, but the effects are often modest and not always clinically significant. In healthy, young, exercising individuals, the evidence is even thinner. A few studies show slight improvements in body composition, but many show no significant difference in strength or muscle size compared to placebo.

Limits and missing context

A 15-second clip cannot convey the full picture. First, MK-677 is not approved by regulatory agencies for any use; it is a research chemical. Second, the side-effect profile is non-trivial: increased hunger, insulin resistance, fluid retention, and elevated blood pressure are commonly reported. Third, the 90-day timeline is arbitrary—some studies use 12 weeks, others 6 months, and results vary widely. Fourth, individual response depends on age, baseline hormone levels, diet, training, and sleep. Finally, the clip does not mention that any gains may be lost after discontinuation.

How this maps to research compounds

If you are exploring growth hormone secretagogues for research, the catalog includes several relevant options. Ipamorelin is often chosen for its relatively selective GH release and fewer hunger effects. Hexarelin is more potent but may cause more desensitization. GHRP-6 is known for strong hunger stimulation. Sermorelin is a GHRH analog, acting through a different pathway. None of these are MK-677, but they occupy the same research niche. The catalog also offers blends like CJC & IPA BLEND for convenience, but each compound should be studied individually.

It is important to note that MK-677 is not listed in the catalog. The compounds listed are for research use only, and their effects in humans are not fully established.

Research-use caveat

All compounds mentioned are for laboratory research and in vitro studies only, not for human or veterinary use. They are not approved by the FDA or any other regulatory body. Researchers must handle them with appropriate safety protocols and comply with all applicable laws. The claims in the clip are anecdotal and not supported by rigorous clinical evidence.